IDEXX Laboratories has fallen sharply year to date, yet recent acquisition activity keeps reshaping its cash flow story, which raises a straightforward question for investors about what the current share price is really paying for.
- The stock is down 22.3% year to date. Anyone looking at IDEXX today is effectively being asked whether that reset lines up with the cash it can generate.
- IDEXX’s purchase of CoVetAI, an AI-powered veterinary scribe and workflow platform, may support expectations for future cash flows if it improves practice efficiency and deepens software adoption in clinics.
- Prefer to judge IDEXX Laboratories on earnings? See why IDEXX Laboratories's 36.0x P/E tells a different valuation story.
The stock’s next move may depend on whether IDEXX Laboratories’ current price can be explained by its expected cash flows when measured against an intrinsic value estimate based on its Discounted Cash Flow (DCF) model.
If you want a broader watchlist of companies where cash flow is in focus, a good next step is to run a targeted screen using 33 healthcare AI stocks.
Does IDEXX Laboratories Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here uses IDEXX Laboratories’ future free cash flows to assess what today’s $520.31 share price is tied to. On the latest twelve month view, IDEXX generated around $1.22b in free cash flow in $. The projection set used in this model assumes those cash flows keep growing rather than shrinking, with 2 Stage Free Cash Flow to Equity estimates stepping up into the early 2030s before settling into steadier expansion.
Those inputs produce an intrinsic value estimate that sits modestly above where the stock trades today. Because the recent CoVetAI acquisition targets AI tools that could deepen practice software usage and support workflow efficiency, the deal helps explain why the cash flow path backing that valuation still assumes IDEXX Laboratories keeps scaling its software contribution over time. That gap between price and modelled worth is what the DCF is highlighting for you to consider. Find out what IDEXX Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.
The IDEXX Laboratories Narrative: What Would Justify Today's Price?
Narratives for IDEXX Laboratories pick up where the DCF puzzle leaves off and spell out which future paths for growth, margins and earnings would need to hold for the stock to end up worth meaningfully more or less than today’s price on Simply Wall St’s Community page. Instead of giving a single valuation figure, they unpack the business assumptions sitting underneath that number so you can track over time whether those moving parts actually play out.
One of the top community narratives on IDEXX Laboratories: 26% undervalued
"The main factor that has to go right is that IDEXX Laboratories converts underpenetrated veterinary diagnostics demand into higher bloodwork inclusion…"
Discover why this Narrative puts IDEXX Laboratories at 26% undervalued.
IDEXX Laboratories: why the story is not complete with the share price
Price and cash flow only tell part of the IDEXX Laboratories picture, since Simply Wall St’s broader checks also flag specific concerns that deserve a closer look before you rely on any valuation alone. Take a closer look at 1 warning sign before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com